# Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

> **NCT03074032** · PHASE1 · COMPLETED · sponsor: **Avionco LLC** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** ONC1-0013B

## Key facts

- **NCT ID:** NCT03074032
- **Lead sponsor:** Avionco LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-30
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074032, "Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03074032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*